Literature DB >> 10949726

Polymorphonuclear leukocyte myeloperoxidase levels in patients with Behçet's disease.

A Accardo-Palumbo1, G Triolo, M C Carbone, A Ferrante, F Ciccia, E Giardina, G Triolo.   

Abstract

Myeloperoxidase was measured in the plasma and in the supernatants of polymorphonuclear granulocyte cultures from patients with Behçet's disease. High levels were found in both plasma and supernatants from patients with active disease. The addition of pentoxifylline to granulocyte cultures determined a significant decrease of myeloperoxidase levels in active patients only. Hyperactive neutrophils are present during the course of Behçet's disease and may be considered of importance in the pathogenesis of the vascular lesions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10949726

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  9 in total

Review 1.  Behçet's disease: from Hippocrates to the third millennium.

Authors:  D H Verity; G R Wallace; R W Vaughan; M R Stanford
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

2.  Circulating neutrophils in Behçet disease is resistant for apoptotic cell death in the remission phase of uveitis.

Authors:  Keita Fujimori; Keiko Oh-i; Masaru Takeuchi; Naoyuki Yamakawa; Takaaki Hattori; Takeshi Kezuka; Hiroshi Keino; Jun Suzuki; Hiroshi Goto; Jun-ichi Sakai; Masahiko Usui
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-10       Impact factor: 3.117

3.  Pentoxifylline influences the autocrine function of organ cultured donor corneas and enhances endothelial cell survival.

Authors:  A C Ventura; M Böhnke
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

4.  Increased myeloperoxidase plasma levels in rheumatoid arthritis.

Authors:  Raissa Maria Sampaio Neves Fernandes; Neusa Pereira da Silva; Emília Inoue Sato
Journal:  Rheumatol Int       Date:  2011-02-18       Impact factor: 2.631

5.  Increased plasma myeloperoxidase levels in systemic lupus erythematosus.

Authors:  Rosa Weiss Telles; Gilda Aparecida Ferreira; Neusa Pereira da Silva; Emilia Inoue Sato
Journal:  Rheumatol Int       Date:  2009-07-29       Impact factor: 2.631

6.  Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behçet's disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity.

Authors:  Antonina Accardo-Palumbo; Anna Rita Giardina; Francesco Ciccia; Angelo Ferrante; Alfonso Principato; Rosalia Impastato; Ennio Giardina; Giovanni Triolo
Journal:  Arthritis Res Ther       Date:  2010-06-03       Impact factor: 5.156

7.  A panel of oxidative stress assays does not provide supplementary diagnostic information in Behcet's disease patients.

Authors:  Yasemin D Akcay; Ferhan G Sagin; Kenan Aksu; Gokhan Keser; Emma Taylor; Iona Knight; Paul G Winyard; Eser Y Sozmen
Journal:  J Inflamm (Lond)       Date:  2012-04-03       Impact factor: 4.981

8.  Do synovial biopsies help to support evidence for involvement of innate immunity in the immunopathology of Behçet's disease?

Authors:  Jan A M van Laar; Jasper H Kappen; Paul L A van Daele; P Martin van Hagen
Journal:  Arthritis Res Ther       Date:  2009-04-30       Impact factor: 5.156

9.  Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behçet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease.

Authors:  Giovanni Triolo; Antonina Accardo-Palumbo; Francesco Dieli; Francesco Ciccia; Angelo Ferrante; Ennio Giardina; Caterina Di Sano; Giuseppe Licata
Journal:  Arthritis Res Ther       Date:  2003-06-30       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.